AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Sopharma AD

Regulatory Filings Apr 5, 2022

2543_rns_2022-04-05_95cf8ec3-7e3d-496c-bc06-65853352e649.pdf

Regulatory Filings

Open in Viewer

Opens in native device viewer

Current report №14/ 2022 Dated April 5, 2022

NOTIFICATION

"Sopharma" AD (the Company) notifies that for March 2022 the Company recorded a decrease in sales of 23% compared to the same month of the previous year, incl. 10% increase in domestic sales and 55% decrease in export sales. The reduced activity on the main foreign markets is a result of Russia's hostile invasion of Ukraine and consequently the Company's inability to maintain a normal supply of pharmaceutical, OTC and other health-related products to the countries participating in the war.

For the first quarter the revenues from sales of products increase by 29%, incl. 80% increase of sales for the domestic market and 3% decrease in export sales.

Ognian Donev

Talk to a Data Expert

Have a question? We'll get back to you promptly.